Clinical Trial Update: A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients [Phase 2]

View source ↗

Summary

Phase 2 open-label, dose-finding study evaluating safety and tolerability of beraprost sodium modified release in pulmonary arterial hypertension patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• beraprost sodium modified release (beraprost sodium modified release)

Snippet

Sponsor: Lung Biotechnology PBC | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2020-06-09